Cargando…
Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis
BACKGROUND/AIMS: Studies have shown that nucleos(t)ide analogue (NA) treatment can reduce the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients, but it is unclear which NA is most effective. We performed a meta-analysis and systematic review comparing the efficacies of NAs...
Autores principales: | Wang, Xinhui, Liu, Xiaoli, Dang, Zhibo, Yu, Lihua, Jiang, Yuyong, Wang, Xianbo, Yang, Zhiyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial Office of Gut and Liver
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096226/ https://www.ncbi.nlm.nih.gov/pubmed/31158948 http://dx.doi.org/10.5009/gnl18546 |
Ejemplares similares
-
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
por: Jung, Sang Kyung, et al.
Publicado: (2015) -
Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B
por: Kim, Soon Sun, et al.
Publicado: (2011) -
Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B
por: Lee, I-Cheng, et al.
Publicado: (2015) -
Impact of gender as a prognostic factor in HBV-related Hepatocellular Carcinoma: the survival strength of female patients in BCLC stage 0-B
por: Yu, Lihua, et al.
Publicado: (2019) -
Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?
por: Yip, Terry Cheuk-Fung, et al.
Publicado: (2020)